MRNA news · MRNA stock

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

Yahoo Finance · Sep 2, 2026 · Moderna Inc (MRNA)

GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.